## RESOURCES [![cover page](https://www.gastrobim.com/images/2026/05/04/gastrobim_sellsheet.webp)](https://www.gastrobim.com/media/attachments/2026/05/05/gastrobim-detailer.pdf) [ Detailer](https://www.gastrobim.com/media/attachments/2026/05/05/gastrobim-detailer.pdf) [ SDS](https://www.gastrobim.com/media/attachments/2026/04/20/gastrobim-us-sds.pdf) [ Data Sheet](https://www.gastrobim.com/media/attachments/2026/04/20/gastrobim_techsheet.pdf) [ Package Insert](https://www.gastrobim.com/dosage-safety) [ FDA Press Release](https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-omeprazole-oral-paste-gastric-ulcers-horses) [ Launch Press Release](https://www.gastrobim.com/about/bimeda-announces-u-s-availability-of-gastrobim) #### Key Research Studies Supporting GASTROBIM™ Bimeda Animal Health | First FDA-Approved Generic Omeprazole Oral Paste | ANADA The following four studies establish the clinical evidence base for omeprazole in the treatment and prevention of Equine Gastric Ulcer Syndrome (EGUS). GASTROBIM™ (omeprazole) oral paste is bioequivalent to GastroGard® and carries the same FDA-approved indications: treatment at 4 mg/kg SID × 28 days and prevention of recurrence at 2 mg/kg SID × 28 days. [![Image](https://www.gastrobim.com/images/2026/06/04/study1.webp)](https://pubmed.ncbi.nlm.nih.gov/24102898/) **Study 1 — Sykes et al. (2013) — Equine Veterinary Journal** *"A Comparison of Two Doses of Omeprazole in the Treatment of EGUS"* **Design:** Blinded, randomized, dose-response clinical trial. **Animals:** 20 Thoroughbred racehorses with grade ≥2/4 squamous and/or glandular ulceration confirmed on gastroscopy. **Key Findings:** A significant dose-response was demonstrated for squamous ulcer healing. Improvement was more likely with the higher dose (4 mg/kg) for squamous mucosa (P = 0.05). Squamous ulcers improved at a significantly higher rate than glandular ulcers (P = 0.02), establishing omeprazole as the first-line agent for ESGD specifically. **Clinical Relevance:** Confirms ESGD responds robustly to omeprazole PPI therapy and supports the 4 mg/kg treatment dose. *Sykes BW et al. Equine Vet J 2014; 46(4):416–421. PMID: 24102898* [VIEW STUDY ](https://pubmed.ncbi.nlm.nih.gov/24102898/) [![Image](https://www.gastrobim.com/images/2026/06/04/study2.webp)](https://pubmed.ncbi.nlm.nih.gov/15906569/) **Study 2 — *McClure et al. (2005) — Journal of the American Veterinary Medical Association*** *"Efficacy of Omeprazole Paste for Prevention of Recurrence of Gastric Ulcers in Horses in Race Training"* **Design:** Prospective, multicenter, randomized controlled trial. **Animals:** 135 horses in active race training. **Procedures:** Horses with confirmed gastric ulcers were treated with omeprazole at 4 mg/kg PO SID for 28 days, then randomized to sham, 0.5 mg/kg, or 1 mg/kg PO SID for an additional 28-day prevention phase. Gastroscopy performed before and after prevention phase. **Key Findings:** Horses receiving 1 mg/kg had significantly lower ulcer scores than sham-dosed horses. 79% of horses receiving 1 mg/kg omeprazole remained ulcer-free vs. only 16% of sham-treated horses. The 0.5 mg/kg dose was not significantly different from sham. **Clinical Relevance:** Directly supports the 1 mg/kg (2 mg/kg = half-dose label) maintenance protocol for prevention of ulcer recurrence — the same dosing carried on the Gastrobim™ ANADA label. *McClure SR, White GW, Sifferman RL, et al. JAVMA 2005; 226(10):1685–1688. PMID: 15906569* [VIEW STUDY ](https://pubmed.ncbi.nlm.nih.gov/15906569/) [![Image](https://www.gastrobim.com/images/2026/06/04/study3.webp)](https://pubmed.ncbi.nlm.nih.gov/29665126/) **Study 3 — *Mason et al. (2019) — Equine Veterinary Journal \[Meta-Analysis\]*** *"Prophylactic Therapy with Omeprazole for Prevention of EGUS in Horses in Active Training"* **Design:** PRISMA-compliant meta-analysis pooling data from multiple randomized controlled trials. **Objective:** To eliminate reporting bias and evaluate the efficacy of prophylactic omeprazole in the prevention of ESGD in training horses, and to compare prophylactic dosages. **Key Findings:** Omeprazole prophylaxis significantly reduces squamous gastric ulceration in active training horses compared to no prophylaxis. Absolute effect: 566 fewer ulcers per 1,000 horses treated. **Clinical Relevance:** Strongest level of evidence supporting omeprazole prophylaxis for ESGD in performance horses. Reinforces the value of omeprazole maintenance dosing throughout a competitive season. *Mason LV et al. Equine Vet J 2019; 51(6):723–730. PMID: 29665126* [VIEW STUDY ](https://pubmed.ncbi.nlm.nih.gov/29665126/) [![Image](https://www.gastrobim.com/images/2026/06/04/study4.webp)](https://www.ivis.org/sites/default/files/library/aaep/2000/256.pdf) **Study 4 — *Bertone (2000) — AAEP Proceedings*** *"Prevalence of Gastric Ulcers in Elite, Heavy Use Western Performance Horses"* **Design:** Prevalence study using gastroscopy with clinical history collection. **Population:** Elite western performance horses competing under NBHA, NRHA, NCHA, USTRC, team penning, intercollegiate rodeo, and related organizations. **Key Findings:** Gastric ulcer prevalence of approximately 40% documented in elite western performance Quarter Horses subject to frequent travel and intensive training. While possibly lower than Thoroughbred racehorses (up to 93%), this prevalence confirms that western performance horses represent a significant at-risk patient population for ESGD. The Merck Veterinary Manual corroborates: gastric ulcers are found in more than 60% of show horses, event horses, western performance horses, and endurance horses, with prevalence increasing with exercise intensity. **Clinical Relevance:** Directly applicable to barrel racing, reining, cutting, roping, and rodeo horses. The omeprazole treatment and prevention data from Studies 1–3 apply regardless of discipline, as the acid-injury mechanism driving ESGD is the same across breeds and performance types. *Bertone JJ. AAEP Proceedings 2000; Vol. 46:256–259.* [VIEW STUDY ](https://www.ivis.org/sites/default/files/library/aaep/2000/256.pdf) **IMPORTANT SAFETY INFORMATION:** The safety of GASTROBIM™ paste has not been determined in pregnant or lactating mares. For use in horses and foals 4 weeks of age and older. Keep out of reach of children. In case of ingestion, contact a physician. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. ![](https://www.gastrobim.com/images/2026/04/07/fc_austria.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_belgium.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_canada.png)Bimeprazol ![](https://www.gastrobim.com/images/2026/04/07/fc_usa.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_denmark.png)Gastrobim Vet ![](https://www.gastrobim.com/images/2026/04/07/fc_estonia.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_france.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_germany.png)Bimeprazol ![](https://www.gastrobim.com/images/2026/04/07/fc_ireland.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_usa.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_italy.png)Bimeprazol ![](https://www.gastrobim.com/images/2026/04/07/fc_latvia.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_lithuania.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_netherlands.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_spain.png)Bimeprazol ![](https://www.gastrobim.com/images/2026/04/07/fc_usa.png)Gastrobim ![](https://www.gastrobim.com/images/2026/04/07/fc_sweden.png)Gastrobim Vet ![](https://www.gastrobim.com/images/2026/04/07/fc_uk.png)Bimeprazol ![](https://www.gastrobim.com/images/2026/04/07/fc_poland.png)Bimeprazol ### Over a million doses sold globally since 2024.